Q32 Bio develops therapies targeting regulators of the immune system to rebalance immunity in autoimmune and inflammatory diseases. Its lead product candidate bempikibart is an anti-IL-7Rα antibody in Phase 2 trials for alopecia areata. The company also pursues complement pathway inhibitors for additional inflammatory conditions.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -9.5 | — |
| Q3 2025 | 0 | — | -7.4 | — |
| Q4 2025 | 53.7 | — | 57.7 | — |
| Q1 2026 | 0 | — | -7.6 | — |
| Q2 2026 | 0 | — | -8.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Forrester Research, Inc. (FORR), TriSalus Life Sciences, Inc. (TLSI), 1RT Acquisition Corp. (ONCH), Microvast Holdings, Inc. (MVST), Bitzero Holdings Inc. (AIBZ), Nature's Sunshine Products, Inc. (NATR)